文献速递造血干细胞移植与细胞治疗

肠道微生物组与临床因素在异基因HSCT受者急性GVHD中的关联

Associations of the gut microbiome and clinical factors with acute GVHD in allogeneic HSCT recipients.
PubMed 文献 · Blood Adv · 2020-01-01

该研究采用鸟枪法宏基因组测序分析150例成人异基因造血干细胞移植受者移植前后259份粪便样本,发现移植后早期微生物基因丰富度降低、Blautia属和Akkermansia muciniphila丰度降低与急性GVHD发生相关,并首次指出清髓性预处理与肠道菌群改变相关。

要点

  • 清髓性预处理与aGVHD及菌群丰富度和特定菌属丰度降低相关。

核心结论

  • 移植后早期肠道微生物多样性低及Blautia属和Akkermansia muciniphila丰度降低与aGVHD发生相关。
  • 清髓性预处理与肠道菌群改变相关,提示预处理可能通过菌群影响aGVHD。

研究设计与样本

  • 研究纳入150例成人异基因造血干细胞移植受者,采集移植前30天至移植后100天的粪便样本,共259份。
  • 采用鸟枪法宏基因组测序分析微生物组成,并检测微生物和临床因素与后续aGVHD的关联。

主要发现

  • 移植后患者肠道细菌多样性下降,部分患者出现Enterococcus属优势。
  • 36例受者在移植后中位34天(四分位距26-50天)发生aGVHD。

临床怎么用

  • 对于异基因HSCT受者,移植后早期可关注肠道菌群多样性及Blautia属和Akkermansia muciniphila丰度,作为aGVHD风险评估的潜在参考。
  • 清髓性预处理患者可能需更密切监测肠道菌群变化及相关aGVHD风险。

局限性

  • 研究为观察性设计,无法确定肠道菌群与aGVHD的因果关系。
  • 样本量有限,需进一步研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acute graft-versus-host disease (aGVHD) is a leading cause of transplantation-related mortality after allogeneic hematopoietic stem cell transplantation (aHSCT). 16S ribosomal RNA (16S rRNA) gene-based studies have reported that lower gut bacterial diversity and the relative abundance of certain bacteria after aHSCT are associated with aGVHD. Using shotgun metagenomic sequencing and a large cohort, we aimed to confirm and extend these observations. Adult aHSCT recipients with stool samples collected from day -30 to day 100 relative to aHSCT were included. One sample was selected per patient per period (pre-aHSCT (day -30 to day 0), early post-aHSCT (day 1 to day 28), and late post-aHSCT (day 29 to day 100)), resulting in 150 aHSCT recipients and 259 samples. Microbial and clinical factors were tested for differences between time periods and an association with subsequent aGVHD. Patients showed a decline in gut bacterial diversity posttransplant, with several patients developing a dominance of Enterococcus. A total of 36 recipients developed aGVHD at a median of 34 days (interquartile range, 26-50 days) post-aHSCT. Lower microbial gene richness (P = .02), a lower abundance of the genus Blautia (P = .05), and a lower abundance of Akkermansia muciniphila (P = .01) early post-aHSCT was observed in those who developed aGVHD. Myeloablative conditioning was associated with aGVHD along with a reduction in gene richness and abundance of Blautia and A muciniphila. These results confirm low diversity and Blautia being associated with aGVHD. Crucially, we add that pretransplant conditioning is associated with changes in gut microbiota. Investigations are warranted to determine the interplay of gut microbiota and conditioning in the development of aGVHD.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Ilett EE, Jørgensen M, Noguera-Julian M, et al. Associations of the gut microbiome and clinical factors with acute GVHD in allogeneic HSCT recipients. Blood Adv. 2020. PMID: 33232475. doi:10.1182/bloodadvances.2020002677

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。